HP2
MCID: HYP602
MIFTS: 39

Hyperoxaluria, Primary, Type Ii (HP2)

Categories: Eye diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hyperoxaluria, Primary, Type Ii

MalaCards integrated aliases for Hyperoxaluria, Primary, Type Ii:

Name: Hyperoxaluria, Primary, Type Ii 56 13 54 39
D-Glycerate Dehydrogenase Deficiency 56 74 52 58 73
Glyoxylate Reductase/hydroxypyruvate Reductase Deficiency 56 24 52 73
Primary Hyperoxaluria Type 2 24 52 58 71
Glyceric Aciduria 56 52 73
Hp2 56 52 73
Primary Hyperoxaluria, Type Ii 29 6
L-Glyceric Aciduria 58 73
Oxalosis Ii 56 73
Hyperoxaluria Primary Type Ii 73
Primary Hyperoxaluria Type Ii 73
Hyperoxaluria Primary 2 73
Oxalosis 2 52
Ph2 73

Characteristics:

Orphanet epidemiological data:

58
primary hyperoxaluria type 2
Inheritance: Autosomal recessive; Age of onset: Childhood; Age of death: any age;

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
variable severity
some patients may be asymptomatic
onset usually in infancy or early childhood


HPO:

31
hyperoxaluria, primary, type ii:
Inheritance autosomal recessive inheritance
Onset and clinical course variable expressivity


Classifications:

Orphanet: 58  
Rare renal diseases
Inborn errors of metabolism


External Ids:

OMIM 56 260000
OMIM Phenotypic Series 56 PS259900
MeSH 43 D006960
ICD10 via Orphanet 33 E74.8
UMLS via Orphanet 72 C0268165
Orphanet 58 ORPHA93599
MedGen 41 C0268165
UMLS 71 C0268165

Summaries for Hyperoxaluria, Primary, Type Ii

NIH Rare Diseases : 52 Primary hyperoxaluria type 2 is a rare condition characterized by the overproduction of a substance called oxalate (also called oxalic acid). In the kidneys, the excess oxalate combines with calcium to form calcium oxalate, a hard compound that is the main component of kidney stones. Deposits of calcium oxalate can lead to kidney damage, kidney failure, and injury to other organs . Primary hyperoxaluria type 2 is caused by the shortage (deficiency) of an enzyme called glyoxylate reductase/hydroxypyruvate reductase (GRHPR) that normally prevents the buildup of oxalate. This enzyme shortage is caused by mutations in the GRHPR gene . Primary hyperoxaluria type 2 is inherited in an autosomal recessive pattern.

MalaCards based summary : Hyperoxaluria, Primary, Type Ii, also known as d-glycerate dehydrogenase deficiency, is related to d-glyceric aciduria and primary hyperoxaluria. An important gene associated with Hyperoxaluria, Primary, Type Ii is GRHPR (Glyoxylate And Hydroxypyruvate Reductase). The drug Pharmaceutical Solutions has been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and ovary, and related phenotypes are nephrocalcinosis and nephrolithiasis

UniProtKB/Swiss-Prot : 73 Hyperoxaluria primary 2: A disorder characterized by elevated urinary excretion of oxalate and L-glycerate, progressive tissue accumulation of insoluble calcium oxalate, nephrolithiasis, nephrocalcinosis, and end-stage renal disease.

Wikipedia : 74 D-glycerate dehydrogenase deficiency or PHGDH is a rare autosomal metabolic disease where the young... more...

More information from OMIM: 260000 PS259900
GeneReviews: NBK2692

Related Diseases for Hyperoxaluria, Primary, Type Ii

Diseases in the Primary Hyperoxaluria family:

Hyperoxaluria, Primary, Type I Hyperoxaluria, Primary, Type Ii
Hyperoxaluria, Primary, Type Iii

Diseases related to Hyperoxaluria, Primary, Type Ii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 d-glyceric aciduria 13.0
2 primary hyperoxaluria 11.8
3 hyperoxaluria, primary, type iii 11.3
4 pulmonary hypertension, primary, 2 10.6
5 nephrolithiasis, calcium oxalate 10.4
6 microcephaly 10.4
7 hyperoxaluria, primary, type i 10.3
8 glycine encephalopathy 10.3
9 metabolic acidosis 10.3
10 encephalopathy 10.3
11 hypotonia 10.3
12 autosomal recessive disease 10.3
13 hermansky-pudlak syndrome 1 10.3
14 hermansky-pudlak syndrome 2 10.3
15 yemenite deaf-blind hypopigmentation syndrome 10.2
16 branchiootic syndrome 1 10.2
17 west syndrome 10.2
18 cortical blindness 10.2
19 nephrocalcinosis 10.2
20 acute kidney failure 10.2
21 early myoclonic encephalopathy 10.2
22 kidney disease 10.2
23 inherited metabolic disorder 10.2
24 end stage renal failure 10.2
25 cerebral atrophy 10.2
26 atrial standstill 1 10.1
27 hair whorl 10.1
28 pulmonary hypertension, primary, 3 10.1
29 inflammatory bowel disease 10.1
30 colitis 10.1
31 allergic hypersensitivity disease 10.1
32 colon adenocarcinoma 10.1
33 breast adenocarcinoma 10.1
34 thyroid carcinoma 10.1
35 sperm protamine p4 10.1
36 spherocytosis, type 1 10.1
37 stroke, ischemic 10.1
38 sickle cell anemia 10.1
39 malaria 10.1
40 spherocytosis, type 2 10.1
41 carotid stenosis 10.1
42 cerebrovascular disease 10.1
43 47,xyy 10.1
44 haemophilus influenzae 10.1
45 rapidly involuting congenital hemangioma 10.1
46 hemolytic uremic syndrome, atypical 1 10.0
47 hemolytic-uremic syndrome 10.0
48 thrombocytopenia 10.0
49 restrictive cardiomyopathy 10.0
50 hemolytic anemia 10.0

Graphical network of the top 20 diseases related to Hyperoxaluria, Primary, Type Ii:



Diseases related to Hyperoxaluria, Primary, Type Ii

Symptoms & Phenotypes for Hyperoxaluria, Primary, Type Ii

Human phenotypes related to Hyperoxaluria, Primary, Type Ii:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nephrocalcinosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000121
2 nephrolithiasis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000787
3 hyperoxaluria 58 31 hallmark (90%) Very frequent (99-80%) HP:0003159
4 recurrent urinary tract infections 58 31 frequent (33%) Frequent (79-30%) HP:0000010
5 ureteral obstruction 58 31 frequent (33%) Frequent (79-30%) HP:0006000
6 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
7 aminoaciduria 31 HP:0003355
8 hematuria 31 HP:0000790
9 calcium oxalate nephrolithiasis 31 HP:0008672

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Kidneys:
hematuria
nephrocalcinosis
renal failure (in some patients)
calcium oxalate urolithiasis

Laboratory Abnormalities:
increased urinary oxylate
increased urinary l-glycerate
decreased grhpr activity

Clinical features from OMIM:

260000

Drugs & Therapeutics for Hyperoxaluria, Primary, Type Ii

Drugs for Hyperoxaluria, Primary, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
2 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
3 Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network Recruiting NCT02026388

Search NIH Clinical Center for Hyperoxaluria, Primary, Type Ii

Genetic Tests for Hyperoxaluria, Primary, Type Ii

Genetic tests related to Hyperoxaluria, Primary, Type Ii:

# Genetic test Affiliating Genes
1 Primary Hyperoxaluria, Type Ii 29 GRHPR

Anatomical Context for Hyperoxaluria, Primary, Type Ii

MalaCards organs/tissues related to Hyperoxaluria, Primary, Type Ii:

40
Kidney, Liver, Ovary, Eye, Colon, Thyroid, Breast

Publications for Hyperoxaluria, Primary, Type Ii

Articles related to Hyperoxaluria, Primary, Type Ii:

(show all 43)
# Title Authors PMID Year
1
Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). 54 24 56 6
11030416 2000
2
The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. 54 56 6
10484776 1999
3
Ethnic differences in GRHPR mutations in patients with primary hyperoxaluria type 2. 56 6
24116921 2014
4
Primary hyperoxaluria. 24 6
23944302 2013
5
Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. 24 6
14635115 2003
6
Primary Hyperoxaluria Type 2 6
20301742 2008
7
Primary hyperoxaluria type 2. 56
9243228 1997
8
Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children. 56
2040928 1991
9
Coenzyme specificity of mammalian liver D-glycerate dehydrogenase. 56
2689175 1989
10
Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. 56
3974685 1985
11
L-Glyceric aciduria (primary hyperoxaluria type 2) in siblings in two unrelated families. 56
6434867 1984
12
Hyperoxaluria in L-glyceric aciduria: possible pathogenic mechanism. 56
4321474 1971
13
L-glyceric aciduria. A new genetic variant of primary hyperoxaluria. 56
5635456 1968
14
Combined Liver-Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report. 24
28681512 2018
15
A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. 24
27924398 2017
16
Calcified nodules on fingers in primary hyperoxaluria type 2. 24
26542998 2016
17
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. 24
22547750 2012
18
Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. 24
21295813 2011
19
Metabolic syndrome and bariatric surgery in stone disease etiology. 24
21191301 2011
20
The effect of restrictive bariatric surgery on urinary stone risk factors. 24
20381135 2010
21
Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation. 24
19118878 2009
22
Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. 24
18501812 2008
23
Nephrolithiasis after bariatric surgery for obesity. 24
18359397 2008
24
A novel mutation in the GRHPR gene in a Japanese patient with primary hyperoxaluria type 2. 24
17510093 2007
25
Bariatric surgery, hyperoxaluria, and nephrolithiasis: a plea for close postoperative management of risk factors. 24
17597787 2007
26
Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. 24
17222634 2007
27
Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. 24
16955107 2006
28
Secondary oxalosis due to excess vitamin C intake. 24
17080154 2006
29
Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2. 24
16597637 2006
30
Structural basis of substrate specificity in human glyoxylate reductase/hydroxypyruvate reductase. 24
16756993 2006
31
Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells. 24
16309382 2006
32
Images in cardiovascular medicine. Cardiomyopathy resulting from primary hyperoxaluria type II. 24
16432059 2006
33
Tissue differences in the expression of mutations and polymorphisms in the GRHPR gene and implications for diagnosis of primary hyperoxaluria type 2. 24
16306119 2005
34
Mitochondrial hydroxyproline metabolism: implications for primary hyperoxaluria. 24
15849464 2005
35
The impact of dietary oxalate on kidney stone formation. 24
15221245 2004
36
A young patient with end-stage renal disease, dyspnoea, weakness, peripheral neuropathy and an unsuspected underlying disease. 24
12897114 2003
37
Primary hyperoxaluria type 2 in children. 24
12185464 2002
38
The primary hyperoxalurias. 24
11518794 2001
39
Primary hyperoxaluria type 2 without L-glycericaciduria: is the disease under-diagnosed? 24
11477177 2001
40
Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. 24
11135054 2001
41
Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. 24
9463747 1998
42
Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. 24
8865249 1996
43
Further studies on the activity and subcellular distribution of alanine:glyoxylate aminotransferase in the livers of patients with primary hyperoxaluria type 1. 61
3416563 1988

Variations for Hyperoxaluria, Primary, Type Ii

ClinVar genetic disease variations for Hyperoxaluria, Primary, Type Ii:

6 (show top 50) (show all 88) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GRHPR NM_012203.2(GRHPR):c.862_863TG[2] (p.Val289fs)short repeat Pathogenic 162020 rs180177321 9:37432132-37432133 9:37432135-37432136
2 GRHPR NM_012203.2(GRHPR):c.246_247TG[1] (p.Val83fs)short repeat Pathogenic 162021 rs672601351 9:37425950-37425951 9:37425953-37425954
3 GRHPR NM_012203.2(GRHPR):c.-4_-3delinsATindel Pathogenic 204230 rs796052077 9:37422744-37422745 9:37422747-37422748
4 GRHPR NM_012203.2(GRHPR):c.45del (p.Ala17fs)deletion Pathogenic 204245 rs180177311 9:37422792-37422792 9:37422795-37422795
5 GRHPR NM_012203.2(GRHPR):c.84-2A>GSNV Pathogenic 204241 rs180177319 9:37424840-37424840 9:37424843-37424843
6 GRHPR NM_012203.2(GRHPR):c.203T>C (p.Leu68Pro)SNV Pathogenic 204232 rs180177305 9:37424961-37424961 9:37424964-37424964
7 GRHPR NM_012203.2(GRHPR):c.287G>T (p.Arg96Leu)SNV Pathogenic 204233 rs796052078 9:37425991-37425991 9:37425994-37425994
8 GRHPR NM_012203.2(GRHPR):c.288-2_288deldeletion Pathogenic 204247 rs796052081 9:37426531-37426533 9:37426534-37426536
9 GRHPR NM_012203.2(GRHPR):c.375del (p.Leu126fs)deletion Pathogenic 204249 rs180177308 9:37426621-37426621 9:37426624-37426624
10 GRHPR NM_012203.2(GRHPR):c.478G>A (p.Gly160Arg)SNV Pathogenic 204234 rs180177312 9:37428554-37428554 9:37428557-37428557
11 GRHPR NM_012203.2(GRHPR):c.540del (p.Leu181fs)deletion Pathogenic 204251 rs180177315 9:37429773-37429773 9:37429776-37429776
12 GRHPR NM_012203.2(GRHPR):c.608_609del (p.Pro203fs)deletion Pathogenic 204252 rs180177316 9:37430517-37430518 9:37430520-37430521
13 GRHPR NM_012203.2(GRHPR):c.694del (p.Gln232fs)deletion Pathogenic 204253 rs796052082 9:37430602-37430602 9:37430605-37430605
14 GRHPR NM_012203.2(GRHPR):c.743T>A (p.Val248Asp)SNV Pathogenic 204236 rs796052079 9:37432013-37432013 9:37432016-37432016
15 GRHPR NM_012203.2(GRHPR):c.905G>A (p.Arg302His)SNV Pathogenic 204237 rs180177323 9:37436697-37436697 9:37436700-37436700
16 GRHPR NM_012203.2(GRHPR):c.934A>G (p.Asn312Asp)SNV Pathogenic 204238 rs180177324 9:37436726-37436726 9:37436729-37436729
17 GRHPR NM_012203.2(GRHPR):c.965T>C (p.Met322Thr)SNV Pathogenic 204240 rs180177325 9:37436757-37436757 9:37436760-37436760
18 GRHPR NM_012203.2(GRHPR):c.965T>G (p.Met322Arg)SNV Pathogenic 204239 rs180177325 9:37436757-37436757 9:37436760-37436760
19 GRHPR NM_012203.2(GRHPR):c.356_369dup (p.Arg124fs)duplication Pathogenic 204248 rs1554746962 9:37426597-37426598 9:37426600-37426601
20 GRHPR NM_012203.2(GRHPR):c.103del (p.Asp35fs)deletion Pathogenic 5636 rs80356708 9:37424859-37424859 9:37424862-37424862
21 GRHPR NM_012203.2(GRHPR):c.295C>T (p.Arg99Ter)SNV Pathogenic 5637 rs119490108 9:37426542-37426542 9:37426545-37426545
22 GRHPR NM_012203.2(GRHPR):c.454dup (p.Thr152fs)duplication Pathogenic/Likely pathogenic 371016 rs771019056 9:37428529-37428530 9:37428532-37428533
23 GRHPR NM_012203.2(GRHPR):c.404+3_404+6delshort repeat Pathogenic/Likely pathogenic 204250 rs180177309 9:37426650-37426653 9:37426653-37426656
24 GRHPR NM_012203.2(GRHPR):c.781_782delinsTAC (p.Gly261fs)indel Pathogenic/Likely pathogenic 551312 rs1554748528 9:37432051-37432052 9:37432054-37432055
25 GRHPR NM_012203.2(GRHPR):c.494G>A (p.Gly165Asp)SNV Pathogenic/Likely pathogenic 204235 rs180177314 9:37429729-37429729 9:37429732-37429732
26 GRHPR NM_012203.2(GRHPR):c.863del (p.Cys288fs)deletion Likely pathogenic 556976 rs1554748598 9:37432133-37432133 9:37432136-37432136
27 GRHPR NM_012203.2(GRHPR):c.214+1G>CSNV Likely pathogenic 552245 rs1244822375 9:37424973-37424973 9:37424976-37424976
28 GRHPR NM_012203.2(GRHPR):c.496del (p.Gln166fs)deletion Likely pathogenic 550345 rs1554747871 9:37429730-37429730 9:37429733-37429733
29 GRHPR NM_012203.2(GRHPR):c.405-1G>ASNV Likely pathogenic 554052 rs779208888 9:37428480-37428480 9:37428483-37428483
30 GRHPR NM_012203.2(GRHPR):c.617_671del (p.Ala206fs)deletion Likely pathogenic 599224 rs1564300888 9:37430524-37430578 9:37430527-37430581
31 GRHPR NM_012203.2(GRHPR):c.102G>A (p.Trp34Ter)SNV Likely pathogenic 204231 rs180177304 9:37424860-37424860 9:37424863-37424863
32 GRHPR NM_012203.2(GRHPR):c.904C>T (p.Arg302Cys)SNV Likely pathogenic 162022 rs180177322 9:37436696-37436696 9:37436699-37436699
33 GRHPR NM_012203.2(GRHPR):c.337G>A (p.Glu113Lys)SNV Likely pathogenic 188765 rs180177307 9:37426584-37426584 9:37426587-37426587
34 GRHPR NM_012203.2(GRHPR):c.735-1G>ASNV Likely pathogenic 204244 rs180177317 9:37432004-37432004 9:37432007-37432007
35 GRHPR NM_012203.2(GRHPR):c.493+2T>ASNV Likely pathogenic 204243 rs180177313 9:37428571-37428571 9:37428574-37428574
36 GRHPR NM_012203.2(GRHPR):c.515del (p.Leu172fs)deletion Likely pathogenic 371081 rs1057516990 9:37429750-37429750 9:37429753-37429753
37 GRHPR NM_012203.2(GRHPR):c.597del (p.Phe199fs)deletion Likely pathogenic 370176 rs1057516292 9:37429830-37429830 9:37429833-37429833
38 GRHPR NM_012203.2(GRHPR):c.755dup (p.Asp252fs)duplication Likely pathogenic 370863 rs1057516823 9:37432024-37432025 9:37432027-37432028
39 GRHPR NM_012203.2(GRHPR):c.954del (p.Glu320fs)deletion Likely pathogenic 370871 rs1057516831 9:37436746-37436746 9:37436749-37436749
40 GRHPR NM_012203.2(GRHPR):c.1A>T (p.Met1Leu)SNV Likely pathogenic 556994 rs1554746094 9:37422748-37422748 9:37422751-37422751
41 GRHPR NM_012203.2(GRHPR):c.214+1G>TSNV Likely pathogenic 551339 rs1244822375 9:37424973-37424973 9:37424976-37424976
42 GRHPR NM_012203.2(GRHPR):c.2T>G (p.Met1Arg)SNV Likely pathogenic 551406 rs1554746097 9:37422749-37422749 9:37422752-37422752
43 GRHPR NM_012203.2(GRHPR):c.154del (p.Ala52fs)deletion Likely pathogenic 371365 rs751101495 9:37424908-37424908 9:37424911-37424911
44 GRHPR NM_012203.2(GRHPR):c.214+2T>GSNV Likely pathogenic 371598 rs1057517398 9:37424974-37424974 9:37424977-37424977
45 GRHPR NM_012203.2(GRHPR):c.228dup (p.Val77fs)duplication Likely pathogenic 371394 rs1057517238 9:37425929-37425930 9:37425932-37425933
46 GRHPR NM_012203.2(GRHPR):c.337G>T (p.Glu113Ter)SNV Likely pathogenic 371535 rs180177307 9:37426584-37426584 9:37426587-37426587
47 GRHPR NM_012203.2(GRHPR):c.404del (p.Asn135fs)deletion Likely pathogenic 370187 rs1057516299 9:37426650-37426650 9:37426653-37426653
48 GRHPR NM_012203.2(GRHPR):c.435_436del (p.Trp145fs)deletion Likely pathogenic 371518 rs1057517333 9:37428511-37428512 9:37428514-37428515
49 GRHPR NM_012203.2(GRHPR):c.437_438TG[2] (p.Cys147fs)short repeat Likely pathogenic 371124 rs1057517026 9:37428513-37428514 9:37428516-37428517
50 GRHPR NM_012203.2(GRHPR):c.188_189del (p.Val63fs)deletion Likely pathogenic 550123 rs1554746565 9:37424945-37424946 9:37424948-37424949

Expression for Hyperoxaluria, Primary, Type Ii

Search GEO for disease gene expression data for Hyperoxaluria, Primary, Type Ii.

Pathways for Hyperoxaluria, Primary, Type Ii

GO Terms for Hyperoxaluria, Primary, Type Ii

Sources for Hyperoxaluria, Primary, Type Ii

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....